Biotechnology
exalt
exalt® develops a single-cell functional precision medicine diagnostic test to generate a personalized “Clear-my-Cancer” report, using a proprietary high-throughput technology.
Application
Our technology identifies personalized cancer treatment recommendations by conducting a comprehensive screening of over 100 anti-cancer drugs (all approved within the European Union) on patient-specific viable cancer biopsies.
This single-cell functional precision medicine scFPM diagnostic procedure allows monitoring of treatment effectiveness ex vivo at single-cell level. Through the selective elimination of cancer cells in individual patients from our screening process, we identify the most effective treatment and provide a tailored clinical recommendation for each patient.
Perspective
Our approach has been clinically tested in a prospective study on 56 patients and is currently being evaluated in a randomized clinical trial including 150 patients with results expected in 2025.
Benefit
In our initial clinical study using scFPM, our team recently demonstrated that scFPM offers significant clinical benefits to 54% of patients with aggressive, advanced-stage blood cancers, with 40% showing exceptional responses. Our technology allows for precise treatment matching and rapid turnover, specifically targeting cancer cells while sparing healthy ones, thereby minimizing the side effects of the selected treatments.
